Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €397.20 EUR
Change Today +4.86 / 1.24%
Volume 1.6K
IDP On Other Exchanges
Symbol
Exchange
Mexico
Frankfurt
As of 2:38 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

225 Binney Street

Cambridge, MA 02142

United States

Phone: 617-679-2000

Fax:

antibody used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia (CLL) and two forms of ANCA-associated vasculitis. Non-Hodgkin's lymphoma and CLL are cancers that affect lymphocytes, which are a type of white blood cell that help to fight infection. Rheumatoid arthritis is a chronic disease that occurs when the immune system mistakenly attacks the body's joints, resulting in inflammation, pain and joint damage. ANCA-associated vasculitis is a rare autoimmune disease that largely affects the small blood vessels of the kidneys, lungs, sinuses, and various other organs. GAZYVA (obinutuzumab), in combination with chlorambucil, is indicated for the treatment of patients with previously untreated CLL. The FDA granted GAZYVA therapy designation due to the significance of the positive progression-free survival results from the Phase 3 CLL11 clinical trial and the serious and life threatening nature of CLL. Other FUMADERM (fumaric acid esters), a prolonged-release tablet formulation approved in Germany only for the treatment of adult patients with moderate to severe plaque psoriasis. Psoriasis is a skin disease in which cells build up on the skin surface and form scales and red patches. FAMPYRA (prolonged-release fampridine tablets), is indicated for the improvement of walking ability in adult patients with MS. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. Marketing and Distribution The company promotes its products in the U.S., most of the major countries of the E.U. and Japan primarily through its own sales forces and marketing groups. It uses customary pharmaceutical company practices to market its products and to educate physicians, such as sales representatives calling on individual physicians, advertisements, professional symposia, direct mail, public relations and other methods. The company provides customer service and other related programs for its products, such as disease and product specific websites, insurance research services and order, delivery and fulfillment services. The company distributes its products in the U.S. principally through wholesale distributors of pharmaceutical products, mail order specialty distributors or shipping service providers. In other countries, the distribution of its products varies from country to country, including through wholesale distributors of pharmaceutical products and third party distribution partners who are responsible for most marketing and distribution activities. The company’s product sales to two wholesale distributors, AmerisourceBergen and McKesson, each accounted for approximately 10% of its total revenues for the year ended December 31, 2014. Research and Development Programs For the year ended December 31, 2014, the company’s research and development expenses were $1,893.4 million. Late Stage Product Candidates ZINBRYTA (daclizumab high yield process) ZINBRYTA is a monoclonal antibody that is being tested in RRMS. In 2014, the company announced results from the Phase 3 DECIDE clinical trial, which investigated ZINBRYTA as a potential once-monthly, subcutaneous treatment for RRMS. TYSABRI (natalizumab) In 2013, the company completed patient enrollment in a Phase 3 study of TYSABRI in secondary progressive MS, known as ASCEND. ELOCTATE (Antihemophilic Factor (Recombinant), Fc Fusion Protein) In 2014, ELOCTATE, a recombinant factor VIII Fc fusion protein (rFVIIIFc), was approved by the FDA for the treatment of hemophilia A. In 2014, the company submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for ELOCTA, the trade name for ELOCTATE in the E.U. ALPROLIX (Coagulation Factor IX (Recombinant), Fc Fusion Protein) In 2014, ALPROLIX was approved by the FDA for the treatment of hemophilia B. Pediatric data would be required as part of the MAA for ALPROLIX that the company plans to submit to the EMA. The company has initiated Kids B-LONG, a global pediatric study evaluating the efficacy and safety of recombinant factor IX Fc fusion protein in children with hemophilia B under the age of 12. GAZYVA The Roche Group

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDP:GR €397.20 EUR +4.86

IDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,950 JPY -27.50
Bristol-Myers Squibb Co $65.26 USD +0.26
Celgene Corp $118.68 USD +1.02
Eli Lilly & Co $73.58 USD +0.14
Novo Nordisk A/S kr369.70 DKK +34.70
View Industry Companies
 

Industry Analysis

IDP

Industry Average

Valuation IDP Industry Range
Price/Earnings 34.7x
Price/Sales 10.4x
Price/Book 9.3x
Price/Cash Flow 29.9x
TEV/Sales 10.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN IDEC INC, please visit www.biogenidec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.